Balentine LLC Biogen Inc. Transaction History

Balentine LLC

$2.54 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $36,174 - $41,219	141 Added 14.04%	1,145 $318,000
Q4 2022 Jan 31, 2023	BUY	$252.44 - $306.72 $13,126 - $15,949	52 Added 5.46%	1,004 $278,000
Q3 2022 Oct 26, 2022	SELL	$194.69 - $268.46 $192,159 - $264,970	-987 Reduced 50.9%	952 $254,000
Q2 2022 Oct 26, 2022	BUY	$187.54 - $223.02 $56,637 - $67,352	302 Added 18.45%	1,939 $395,000
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $56,637 - $67,352	302 Added 18.45%	1,939 $395,000
Q1 2022 Oct 26, 2022	SELL	$193.77 - $244.14 $58,518 - $73,730	-302 Reduced 15.58%	1,637 $345,000
Q1 2022 May 06, 2022	BUY	$193.77 - $244.14 $317,201 - $399,657	1,637 New	1,637 $345,000
Q3 2020 Nov 02, 2020	SELL	$264.77 - $305.71 $51,365 - $59,307	-194 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $31,556 - $41,791	122 Added 169.44%	194 $52,000
Q1 2020 May 18, 2020	SELL	$268.85 - $341.04 $35,488 - $45,017	-132 Reduced 64.71%	72 $23,000
Q4 2019 Sep 02, 2020	BUY	$220.06 - $304.07 $36,529 - $50,475	166 Added 436.84%	204 $61,000
Q3 2019 Nov 15, 2019	BUY	$217.44 - $243.88 $2,391 - $2,682	11 Added 40.74%	38 $9,000
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $5,920 - $6,526	27 New	27 $6,000
Q1 2019 May 16, 2019	SELL	$216.71 - $338.96 $34,240 - $53,555	-158 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $46,374 - $60,645	158 New	158 $56,000
Q1 2018 May 16, 2018	SELL	$260.13 - $367.91 $185,732 - $262,687	-714 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $307 - $344	-1 Reduced 0.14%	714 $227,000
Q3 2017 Nov 15, 2017	BUY	$281.15 - $329.69 $201,022 - $235,728	715	715 $224,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.

Account